How to design a theranostic trial?

Area of Science:

• Nuclear Medicine
• Oncology
• Clinical Trial Design

Background:

• The field of nuclear theranostic clinical trials is rapidly expanding for advanced and metastatic cancers.
• Translating scientific research into patient treatments ('bench-to-bedside') is a complex process.
• Theranostics, combining diagnostics and personalized therapy, is a key focus in nuclear medicine.

Purpose of the Study:

• To explore the fundamental elements of designing clinical trials for nuclear medicine theranostics.
• To highlight trends and challenges in each phase of clinical trials for theranostic agents.

Main Methods:

• Review of preclinical study components: in vitro, in vivo, and animal models.
• Outline of clinical trial phases: safety, efficacy, and comparative studies.
• Emphasis on essential components: data management, statistics, GCP, and funding.

Main Results:

• Successful theranostic trial design necessitates meticulous planning, including preclinical validation and phased clinical evaluation.
• Optimization of dosimetry and reduction of adverse effects are critical for radionuclide therapy agents.
• Collaboration among stakeholders is vital for funding and sustainable pricing models.

Conclusions:

• Effective nuclear medicine theranostic clinical trials require robust design, focusing on safety, efficacy, and personalized treatment strategies.
• Addressing challenges in radionuclide therapy, such as non-uniform distribution and complex radiobiology, is essential.
• Successful implementation hinges on collaborative efforts and adherence to Good Clinical Practice (GCP).